Overview

A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis

Status:
Active, not recruiting

Trial end date:
2021-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether etrasimod is a safe and effective treatment for moderate to severe atopic dermatitis (AD).

Phase:

Phase 2

Details

Lead Sponsor:

Arena Pharmaceuticals